In The News |
The U.S. Food and Drug Administration (FDA) recently approved a digital pill embedded with a sensor designed to inform physicians whether their patients are taking their medications. The federal approval marks a growing trend towards addressing drug non-adherence among patients, according to a New York Times report.
The pill, called Abilify MyCite, is a modified version of Otsuka Pharmaceutical’s drug Abilify that is used in the treatment of schizophrenia, bipolar disorder, and depression. It is equipped with a small tracking device developed by Proteus Digital Health. The new tracking pill works by transmitting a message from the sensor to a wearable patch, which then sends data to a mobile app to enable patients to monitor drug ingestion on their smartphone.
|